Dr Ezam Mat Ali
KUALA LUMPUR, Aug 5, 2026 — MedPlanner Sdn. Bhd. has announced a major update to its AI health companion app, AskHEMI, introducing Personalized Health Intelligence and Medication Reminders. The new features aim to make AskHEMI a daily health partner that understands each user’s unique profile.
With Personalized Health Intelligence, AskHEMI learns a user’s health conditions, medications, allergies, lab results, and lifestyle, tailoring every response to their specific context. Users can upload prescriptions or lab reports for instant interpretation, or ask whether a medication is safe based on their personal health data.
The Medication Reminders feature helps users manage daily treatments by setting schedules, receiving timely alerts, and tracking adherence through weekly and monthly charts.
Dr Ezam Mat Ali, Founder and CEO of MedPlanner, said: “By adding greater intelligence to the app, every response is grounded in the user’s own health profile. This update sets us further apart from the many generic AI health apps available today.”
AskHEMI, powered by the HEMI clinical AI engine, also supports multilingual use and image-based health queries. The app is free to download, with affordable subscription plans starting at USD3 per month.
Read More News on Latest Malaysia
Read More News on Business News Malaysia
Read More News on SG Business News
Read More News on World Future TV
Hartalega posted stronger-than-expected first-quarter earnings as higher average selling prices and cost optimisation lifted profitability,…
The award marks another significant milestone for PMG Healthcare Group and reflects the trust and…
Federal Express Corporation (FedEx), one of the world’s largest express transportation companies, has enhanced its…
Technical indicators point to a recovery in Malaysia's consumer sector, while expectations of continued fiscal…
South Korea's inflation slowed in July on lower fuel prices, but persistent core inflation and…
Malaysia's ringgit remained resilient in July despite a weaker US dollar, though analysts expect near-term…
This website uses cookies.